NasdaqGM:URGN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases.


Snowflake Analysis

Flawless balance sheet and slightly overvalued.

Share Price & News

How has UroGen Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: URGN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

4.8%

URGN

0.3%

US Biotechs

3.0%

US Market


1 Year Return

-27.8%

URGN

31.4%

US Biotechs

15.8%

US Market

Return vs Industry: URGN underperformed the US Biotechs industry which returned 31.4% over the past year.

Return vs Market: URGN underperformed the US Market which returned 15.8% over the past year.


Shareholder returns

URGNIndustryMarket
7 Day4.8%0.3%3.0%
30 Day-5.6%-3.9%6.0%
90 Day-2.0%7.8%16.4%
1 Year-27.8%-27.8%33.6%31.4%18.4%15.8%
3 Year29.5%29.5%35.2%28.6%44.8%35.4%
5 Yearn/a7.8%-0.2%75.7%56.7%

Price Volatility Vs. Market

How volatile is UroGen Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is UroGen Pharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: URGN ($23.16) is trading below our estimate of fair value ($160.64)

Significantly Below Fair Value: URGN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: URGN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: URGN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate URGN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: URGN's PB Ratio (3.3x) is in line with the US Biotechs industry average.


Next Steps

Future Growth

How is UroGen Pharma forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

68.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: URGN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: URGN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: URGN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: URGN's revenue (61% per year) is forecast to grow faster than the US market (9.4% per year).

High Growth Revenue: URGN's revenue (61% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: URGN is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has UroGen Pharma performed over the past 5 years?

-57.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: URGN is currently unprofitable.

Growing Profit Margin: URGN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: URGN is unprofitable, and losses have increased over the past 5 years at a rate of 57.8% per year.

Accelerating Growth: Unable to compare URGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: URGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.3%).


Return on Equity

High ROE: URGN has a negative Return on Equity (-80.75%), as it is currently unprofitable.


Next Steps

Financial Health

How is UroGen Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: URGN's short term assets ($121.9M) exceed its short term liabilities ($14.2M).

Long Term Liabilities: URGN's short term assets ($121.9M) exceed its long term liabilities ($2.3M).


Debt to Equity History and Analysis

Debt Level: URGN is debt free.

Reducing Debt: URGN has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: URGN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: URGN has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 57.3% each year.


Next Steps

Dividend

What is UroGen Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate URGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate URGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if URGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if URGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of URGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Liz Barrett (58 yo)

1.58yrs

Tenure

US$25,900,823

Compensation

Ms. Elizabeth A. Barrett, also known as Liz, has been President, Chief Executive Officer and Director of UroGen Pharma Ltd. since January 3, 2019. She served as Chief Executive Officer of Novartis Oncology ...


CEO Compensation Analysis

Compensation vs Market: Liz's total compensation ($USD25.90M) is above average for companies of similar size in the US market ($USD2.10M).

Compensation vs Earnings: Insufficient data to compare Liz's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Elizabeth Barrett
President1.58yrsUS$25.90m0.72%
$ 3.6m
Peter Pfreundschuh
CFO & Secretary2yrsUS$1.35m0.034%
$ 170.3k
Mark Schoenberg
Chief Medical Officer2.67yrsUS$800.91k0.085%
$ 429.5k
Ron Bentsur
1.58yrsUS$699.77kno data
Catherine Bechtold
Senior Director of Investor Relations2.58yrsno datano data
Eric Van Zanten
Senior Director of Communicationsno datano datano data
Sari Prutchi-Sagiv
Marketing Directorno datano datano data
Marina Konorty
Executive Vice President of Research & Development and Technical Operations0.42yrno datano data
Jeffrey Bova
Chief Commercial Officer0.42yrno datano data
James Ottinger
Executive Vice President of Regulatory Affairs & Quality0.42yrno datano data
Elyse Seltzer
Chief Development Officer0.42yrno datano data
Jones Bryan
Senior Vice President of Business Development1.92yrsno datano data

1.6yrs

Average Tenure

55.5yo

Average Age

Experienced Management: URGN's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Elizabeth Barrett
President1.58yrsUS$25.90m0.72%
$ 3.6m
Kathryn Falberg
Independent Director3.33yrsUS$332.70k0.074%
$ 375.6k
Fred Cohen
Independent Director3.25yrsUS$317.70k0.068%
$ 347.4k
Cynthia Butitta
Independent Director2.83yrsUS$335.20kno data
Stuart Holden
Independent Director4.67yrsUS$320.20kno data
Arie Belldegrun
Independent Chairman7.67yrsUS$472.70k1.1%
$ 5.6m
Ran Nussbaum
Independent Director7.25yrsUS$317.78kno data
Jack Baniel
Member of Scientific Advisory Boardno datano datano data
Herbert Lepor
Chairman of Scientific Advisory Boardno datano datano data
Fred Witjes
Member of Scientific Advisory Boardno datano datano data
Shawn Tomasello
Independent Director2.08yrsUS$312.70kno data

3.3yrs

Average Tenure

62.5yo

Average Age

Experienced Board: URGN's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.5%.


Top Shareholders

Company Information

UroGen Pharma Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: UroGen Pharma Ltd.
  • Ticker: URGN
  • Exchange: NasdaqGM
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$508.018m
  • Shares outstanding: 21.94m
  • Website: https://www.urogen.com

Number of Employees


Location

  • UroGen Pharma Ltd.
  • 400 Alexander Park
  • Princeton
  • New Jersey
  • 8540
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
URGNNasdaqGM (Nasdaq Global Market)YesOrdinary SharesUSUSDMay 2017
UR8DB (Deutsche Boerse AG)YesOrdinary SharesDEEURMay 2017
0XODLSE (London Stock Exchange)YesOrdinary SharesGBUSDMay 2017

Biography

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases. The company’s lead product candidates are UGN-101 and UGN-102, w ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/07 23:41
End of Day Share Price2020/08/07 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.